Inc.

Samsara Ranks in Top 15 in the UK’s Best Workplaces™ 2024

Retrieved on: 
Monday, March 18, 2024
Software, Networks, Internet, Data Management, Technology, Logistics, Supply Chain Management, IOT (Internet of Things), Transport, Cloud, Element, Connected, Culture, Inc., Trust, Mental health, Workplace, Workforce, Multimedia, Management

With a continuous employee feedback loop, Samsara listens and evolves its offerings to best reflect the needs of its growing workforce.

Key Points: 
  • With a continuous employee feedback loop, Samsara listens and evolves its offerings to best reflect the needs of its growing workforce.
  • Congratulations to Samsara for being part of our 2024 UK’s Best Workplaces™ List."
  • Great Place To Work® performed rigorous evaluations of hundreds of employee survey responses alongside Culture Audit™ submissions from leaders at each company to create the 2024 UK's Best Workplaces™ list.
  • Only those businesses who achieve the highest scores after evaluation receive Best Workplaces™ status.

Fisker Announces Receipt of Financing Commitment of Up to $150 Million and Provides Business Update

Retrieved on: 
Monday, March 18, 2024
Commercial Building & Real Estate, Construction & Property, Natural Resources, Environment, Other Manufacturing, EV, Electric Vehicles, Engineering, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Mobile, Wireless, Telecommunications, Other Philanthropy, Other Energy, Software, Utilities, Internet, Alternative Energy, Hardware, Automotive, Energy, Technology, Sustainability, Philanthropy, General Automotive, Mining, Minerals, EVS, Inc., Fisker Inc., Automotive News, Toyota, NRV, News

Fisker Inc. (NYSE: FSR) (“Fisker”), driven by a mission to create the world’s most emotional and sustainable electric vehicles, today announced a financing commitment from an existing investor providing up to $150 million of gross proceeds.

Key Points: 
  • Fisker Inc. (NYSE: FSR) (“Fisker”), driven by a mission to create the world’s most emotional and sustainable electric vehicles, today announced a financing commitment from an existing investor providing up to $150 million of gross proceeds.
  • The financing is being provided by the holder of the company’s 2025-dated convertible notes and will be organized in four tranches.
  • Fisker has produced approximately 1,000 vehicles in 2024 through March 15, and has delivered approximately 1,300 globally in that same timeframe.
  • Fisker will pause production for six weeks starting the week of March 18, 2024, to align inventory levels and progress strategic and financing initiatives.

Certain Morgan Stanley Closed-End Funds Declare Quarterly Dividends

Retrieved on: 
Monday, March 18, 2024
Banking, Professional Services, Finance, Inc.

Morgan Stanley Emerging Markets Debt Fund, Inc.

Key Points: 
  • Morgan Stanley Emerging Markets Debt Fund, Inc.
    Morgan Stanley Emerging Markets Domestic Debt Fund, Inc.
  • The amount of net investment income to be paid by the Funds is determined in accordance with federal income tax regulations.
  • It is possible that all or a portion of the Funds’ fiscal year 2024 dividend may be a return of capital and that determination cannot yet be made.
  • The amount of dividends paid by each of the Funds may vary from time to time.

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Toxicity, Administration, Information technology, MECP2, Inc., Patient, Cash, Batten disease, Cohort, Female, Insurance, Rett syndrome, Research and development, Investment, Clinical trial, Net, Data, DSM-IV codes, Pharmaceutical industry

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.

Key Points: 
  • Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.
  • We believe this expanded dataset will support future regulatory discussions to align on the design of a potential registrational study,” said Rachel McMinn, Ph.D., Chief Executive Officer and Founder of Neurogene.
  • “NGN-401 has the potential to be a best-in-class treatment option with a targeted route of administration to deliver full-length, functional copies of the MECP2 gene.
  • Net income for the three months ended December 31, 2023 included a one-time $16.4 million bargain purchase gain related to the reverse merger.

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Retrieved on: 
Friday, March 15, 2024
Research, Mental Health, FDA, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, GAD, Selective serotonin reuptake inhibitor, Breakthrough therapy, Inc., Patient, Disease, Human, Anxiety, DMT, Epidemiology, Psychiatry, Anxiety disorder, Safety, E36, Food, Pharmaceutical industry

“Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.

Key Points: 
  • “Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • The CYB004-002 Phase 2 study is a randomized, double-blind study which will evaluate the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed.
  • The study will enroll participants with moderate to severe GAD and a score of ≥10 on the GAD-7 anxiety scale.
  • Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019.

Enviva Announces Court Approval of DIP and the Commencement of the DIP Syndication Process

Retrieved on: 
Friday, March 15, 2024
Forest Products, Energy, Natural Resources, Other Energy, Enviva, KCC, Common stock, Form 8-K, Telephone, Rule, Date, Inc., CUSIP, DIP, Sale, United States bankruptcy court, Bankruptcy, Suite, Security (finance)

If you are not an Eligible Holder, you may not participate in the Opportunity.

Key Points: 
  • If you are not an Eligible Holder, you may not participate in the Opportunity.
  • Eligible Holders that participate in the Opportunity will be subject to certain restrictions under the DIP Facility Agreement, including with respect to voting and information rights.
  • If you are an Eligible Holder interested in participating in the Opportunity, you must complete copies of the relevant subscription documents.
  • Certain principal terms of the DIP Facility and the Company and certain of its subsidiaries’ contemplated restructuring are set forth in the DIP Facility Agreement, which is available at www.kccllc.com/Enviva (by clicking on the link for “DIP Syndication Materials”).

Jadex Inc. Recognized as U.S. Best-in-Class Employer by Gallagher

Retrieved on: 
Monday, March 18, 2024
Human Resources, Medical Supplies, Health, Packaging, Engineering, Chemicals, Plastics, Professional Services, Manufacturing, Inc., Benefit, Communication

Jadex Inc. was recognized for its comprehensive framework for strategically investing in benefits, compensation and employee communication to support the health, financial security and career growth of its employees at a sustainable cost structure.

Key Points: 
  • Jadex Inc. was recognized for its comprehensive framework for strategically investing in benefits, compensation and employee communication to support the health, financial security and career growth of its employees at a sustainable cost structure.
  • Designations like Gallagher’s Best-in-Class Employer help current and potential employees understand and appreciate an organization’s workplace culture and people strategy; important differentiators as employers compete for talent in today’s labor market.
  • This also allows us to continue to attract and keep the best talent,” said Jeremy Rikala, Chief Human Resources Officer at Jadex.
  • “In doing so, Jadex utilizes data, workforce feedback tools and clearly defined policies to provide competitive benefits and experiences that their employees value.”

Pega Announces Quarterly Cash Dividend for Second Quarter of 2024

Retrieved on: 
Friday, March 15, 2024
Software, Technology, Artificial Intelligence, Inc.

Pegasystems Inc. (NASDAQ: PEGA), the leading enterprise AI decisioning and workflow automation platform provider, today announced a quarterly cash dividend of $0.03 per share, maintaining the company’s current dividend program.

Key Points: 
  • Pegasystems Inc. (NASDAQ: PEGA), the leading enterprise AI decisioning and workflow automation platform provider, today announced a quarterly cash dividend of $0.03 per share, maintaining the company’s current dividend program.
  • The Q2 2024 dividend will be paid on April 15, 2024, to shareholders of record as of April 1, 2024.

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
  • “In 2023, Agenus made significant advances across our BOT/BAL development program.
  • $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
  • For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Retrieved on: 
Thursday, March 14, 2024
Mental Health, Finance, FDA, Clinical Trials, Professional Services, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Depression, Week, DEA, BTD, Inc., MDD, Patient, Accelerated approval (FDA), DSM-IV codes, Suicidal ideation, Behavior, Priority review, Drug development, Major depressive disorder, Pharmaceutical industry

The Company has received minutes from its End-of-Phase-2 meeting with the FDA and reached alignment on its Phase 3 program design.

Key Points: 
  • The Company has received minutes from its End-of-Phase-2 meeting with the FDA and reached alignment on its Phase 3 program design.
  • The Company intends to commence enrollment for the multinational, multisite Phase 3 program in mid-year 2024.
  • The Company has engaged Worldwide Clinical Trials (“Worldwide”), a global, full-service contract research organization with deep expertise managing clinical trials for mental health conditions, including major depressive disorder.
  • Having aligned on key features of the pivotal program, we look forward to initiating a multisite, multinational Phase 3 program around mid-year,” said Doug Drysdale, Chief Executive Officer of Cybin.